Biogen dubs publicly traded hemophilia spinoff Bioverativ, aims for early 2017

Biogen ($BIIB) has fleshed out its plan to spin out its blood disorder products and candidates into a separate publicly traded company. The new co will be known as Bioverativ and is slated to launch in early 2017 and trade on the Nasdaq market.

It will include commercialized hemophilia drugs Eloctate and Alprolix, which are partnered with Swedish Orphan Biovitrum (Sobi), as well as a pipeline including gene therapy programs for hemophilia A and B, a non-factor bispecific antibody program to treat patients with hemophilia A and those with inhibitors, as well as sickle cell disease research.

“We've chosen to spin off our growing hemophilia business, because we believe it's the right decision to ensure fit and focus,” said outgoing Biogen CEO George Scangos on the company’s July earnings call.

He added, “That business continues to perform well, with combined second quarter revenues of over $200 million for Eloctate and Alprolix. Alprolix also was approved by the European Commission for the treatment of hemophilia B and will be commercialized in the EU by our collaboration partner, Sobi.”

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Bioverativ will be headed by CEO John Cox, formerly Biogen EVP of Pharmaceutical Operations & Technology. “The new company’s name creates a clear connection to our Biogen heritage and biotech focus,” he said in a statement. Biogen first announced its spinoff plans earlier this year in May.

The new company is expected to use the revenues from the marketed drugs to support continued R&D in blood disorders. Specifically, it hopes to create longer acting therapies based on its XTEN technology and get this into the clinic during the first half of 2017. In addition, it expects to move faster on the development for bispecific antibodies and hemophilia-related gene therapy programs.

Bioverativ also plans to conduct clinical testing on Eloctate as a potential means to rapidly induce immune tolerance in hemophilia patients who develop inhibitors.

- here is the announcement

Related Articles:
Biogen inks a $100M hemophilia deal with a Polaris-backed startup
BioMarin up on positive gene therapy data in hemophilia A
Shire cans Baxalta hemophilia B gene therapy, thinning field for uniQure, Spark
Biotechs jockey for gene therapy lead with hemophilia data ‘snapshots’
Biogen CEO George Scangos to step down

Suggested Articles

The measure of success for 10x Genomics is not the IPO dollar amount, but instead the discoveries made by researchers using its hardware, the CEO said.

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.